Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Familial amyloid cardiomyopathy due to TTR mutations: an underdiagnosed cause of restrictive cardiomyopathy [corrected]. | Academic Article |
Why?
|
| Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. | Academic Article |
Why?
|
| Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. | Academic Article |
Why?
|
| Ruberg, Frederick | Person |
Why?
|
| Amyloid Cardiomyopathy: Disease on the Rise. | Academic Article |
Why?
|
| Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. | Academic Article |
Why?
|
| Molecular Imaging of Primary Amyloid Cardiomyopathy | Grant |
Why?
|
| Molecular Imaging of Primary Amyloid Cardiomyopathy | Grant |
Why?
|
| Berk, John | Person |
Why?
|
| Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. | Academic Article |
Why?
|
| Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). | Academic Article |
Why?
|
| Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. | Academic Article |
Why?
|
| Mendelson, Lisa | Person |
Why?
|
| Sanchorawala, Vaishali | Person |
Why?
|
| "A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy" | Grant |
Why?
|